Polyrizon shares spiked over 80% premarket after the company said it successfully scaled production of its PL-14 nasal spray from lab batches to controlled, larger manufacturing runs. The breakthrough supports upcoming clinical trials and future commercial supply. Retail sentiment jumped to extremely bullish with high message activity on Stocktwits.